Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 5/20 | 0.48 |
| ▸ | MMP8 | P22894 | 4/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916631 | 0.88 | NPC1 (0.46) | MMP3MMP8MMP1MMP9CSNK1E | |
| SCHEMBL2917355 | 0.88 | NPC1 (0.46) | MMP3MMP8MMP1MMP9CSNK1E | |
| SCHEMBL2910132 | 0.87 | MMP3 (0.47) | MMP3MMP8MMP1MMP9L3MBTL1 | |
| SCHEMBL25120992 | 0.80 | MMP3 (0.50) | MMP3MMP8MMP1MMP9L3MBTL1 | |
| SCHEMBL2915216 | 0.79 | CSNK1E (0.48) | MMP3MMP8MMP1MMP9CSNK1E | |
| SCHEMBL2910314 | 0.79 | CSNK1E (0.48) | MMP3MMP8MMP1MMP9CSNK1E | |
| SCHEMBL3625680 | 0.78 | LTA4H (0.52) | MMP3MMP8MMP1MMP9L3MBTL1 | |
| SCHEMBL20185592 | 0.77 | SMN1; SMN2 (0.43) | MEN1KMT2ALTA4HABCB1MIF | |
| Hydrochloric Acid SCHEMBL3621460 | 0.77 | LTA4H (0.51) | MMP3MMP8MMP1MMP9L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3621454 | 0.77 | LTA4H (0.51) | MMP3MMP8MMP1MMP9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751126-B1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | ABBOTT PRODUCTS GMBH (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1751126-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-7074822-B2 | Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005080366-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | PNLIP, CEL, LIPE | MMP3 2501/4885MMP8 1688/4885MMP1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.